104 related articles for article (PubMed ID: 38941241)
1. A fluorescent gemcitabine prodrug that follows a nucleoside transporter-independent internalization and bears enhanced therapeutic efficacy with respect to gemcitabine.
Vrettos E; Kyrkou S; Zoi V; Giannakopoulou M; Chatziathanasiadou M; Kanaki Z; Agalou A; Bistas VP; Kougioumtzi A; Karampelas T; Diamantis D; Murphy C; Beis D; Klinakis A; Tamvakopoulos C; Kyristis A; Alexiou G; Tzakos A
Chemistry; 2024 Jun; ():e202401327. PubMed ID: 38941241
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
4. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
Zhong H; Mu J; Du Y; Xu Z; Xu Y; Yu N; Zhang S; Guo S
Biomacromolecules; 2020 Feb; 21(2):803-814. PubMed ID: 31995366
[TBL] [Abstract][Full Text] [Related]
5. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
Vrettos EI; Karampelas T; Sayyad N; Kougioumtzi A; Syed N; Crook T; Murphy C; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2021 Feb; 211():113018. PubMed ID: 33223264
[TBL] [Abstract][Full Text] [Related]
6. Development of bioactive gemcitabine-D-Lys
Sayyad N; Vrettos EI; Karampelas T; Chatzigiannis CM; Spyridaki K; Liapakis G; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2019 Mar; 166():256-266. PubMed ID: 30716713
[TBL] [Abstract][Full Text] [Related]
7. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.
Guo B; Wei J; Wang J; Sun Y; Yuan J; Zhong Z; Meng F
Acta Biomater; 2022 Jun; 145():200-209. PubMed ID: 35430336
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Pratt SE; Durland-Busbice S; Shepard RL; Donoho GP; Starling JJ; Wickremsinhe ER; Perkins EJ; Dantzig AH
Mol Cancer Ther; 2013 Apr; 12(4):481-90. PubMed ID: 23371859
[TBL] [Abstract][Full Text] [Related]
9. Small Molecular Gemcitabine Prodrugs for Cancer Therapy.
Miao H; Chen X; Luan Y
Curr Med Chem; 2020; 27(33):5562-5582. PubMed ID: 31419928
[TBL] [Abstract][Full Text] [Related]
10. Recent Development of Prodrugs of Gemcitabine.
Pandit B; Royzen M
Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328020
[TBL] [Abstract][Full Text] [Related]
11. Nanomized tumor-microenvironment-active NIR fluorescent prodrug for ensuring synchronous occurrences of drug release and fluorescence tracing.
Li Q; Cao J; Wang Q; Zhang J; Zhu S; Guo Z; Zhu WH
J Mater Chem B; 2019 Mar; 7(9):1503-1509. PubMed ID: 32255021
[TBL] [Abstract][Full Text] [Related]
12. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
[TBL] [Abstract][Full Text] [Related]
13. Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug.
Lee MH; Kim JY; Han JH; Bhuniya S; Sessler JL; Kang C; Kim JS
J Am Chem Soc; 2012 Aug; 134(30):12668-74. PubMed ID: 22642558
[TBL] [Abstract][Full Text] [Related]
14. Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo.
Tao XM; Wang JC; Wang JB; Feng Q; Gao SY; Zhang LR; Zhang Q
Eur J Pharm Biopharm; 2012 Oct; 82(2):401-9. PubMed ID: 22728546
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
16. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
[TBL] [Abstract][Full Text] [Related]
17. Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
Dong S; He J; Sun Y; Li D; Li L; Zhang M; Ni P
Mol Pharm; 2019 Sep; 16(9):3770-3779. PubMed ID: 31348660
[TBL] [Abstract][Full Text] [Related]
18. Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness.
Zhao W; Yang S; Li C; Li F; Pang H; Xu G; Wang Y; Cong M
Int J Nanomedicine; 2022; 17():3239-3249. PubMed ID: 35924258
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anticancer evaluation of acetylated-lysine conjugated gemcitabine prodrugs.
Wang M; Qu K; Zhao P; Yin X; Meng Y; Herdewijn P; Liu C; Zhang L; Xia X
RSC Med Chem; 2023 Aug; 14(8):1572-1580. PubMed ID: 37593582
[TBL] [Abstract][Full Text] [Related]
20. Tailor-made gemcitabine prodrug nanoparticles from well-defined drug-polymer amphiphiles prepared by controlled living radical polymerization for cancer chemotherapy.
Wang W; Li C; Zhang J; Dong A; Kong D
J Mater Chem B; 2014 Apr; 2(13):1891-1901. PubMed ID: 32261525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
